CERAMENT BONE VOID FILLER
Commercial- Indications
- Bone defects, Bone voids
Company intelligence / Profile preview
BONESUPPORT has commercialized several synthetic injectable bioceramic bone graft substitutes under the CERAMENT brand. These products have demonstrated effective remodeling to host bone within 6–12 months. CERAMENT G has been recognized as a breakthrough device by the FDA and approved in Europe since 2013. The company’s clinical studies support use in trauma, infection-related defects, and other orthopedic indications.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BONESUPPORT.